Catheter-based stem cell and gene therapy for refractory myocardial ischemia

被引：12

作者：

Fuchs S. ^{[1
]}

Battler A. ^{[2
]}

Kornowski R. ^{[3
]}

机构：

[1] Cardiac Catheterization Service, Rabin Medical Center, Petah Tikva

[2] Cardiology Departments, Rabin Medical Center, Petah Tikva

[3] International Cardiology, Rabin Medical Center, Petah Tikva

来源：

Nature Clinical Practice Cardiovascular Medicine | 2007年 / 4卷 / Suppl 1期

关键词：

D O I：

10.1038/ncpcardio0762

中图分类号：

学科分类号：

摘要：

Intramyocardial delivery of genes and cells derived from bone marrow has been evaluated in several small studies of 'no-option' symptomatic patients with chronic ischemic coronary artery disease. Clinical experience with intramyocardial gene delivery is limited to genes encoding isoforms of vascular endothelial cell growth factor. In the largest study (Euroinject One), 80 patients were randomized to receive a plasmid encoding vascular endothelial cell growth factor 165 or placebo. The results of this study suggested no beneficial therapeutic effect of this strategy. The experience with stem cells is limited to use of autologous, nonexpanded, nonmanipulated bone-marrow-derived cells; thus, the number of injected stem cells reflects their natural proportion within the bone marrow. The results of these preliminary studies suggest this approach is feasible and has a high safety profile. Although no conclusion can yet be made regarding efficacy, the improved myocardial perfusion in all four studies described in this Review is encouraging. Data from assessments of individual patients, however, suggests a wide variability in response, underscoring the need for further bench and clinical investigations.

引用

页码：S89 / S95

页数：6

共 28 条

[1]

Thom T., Et al., Heart disease and stroke statistics - 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 113, (2006)

[2]

Mukherjee D., Et al., Direct myocardial revascularization and angiogenesis - How many patients might be eligible?, Am J Cardiol, 84, pp. 598-600, (1999)

[3]

Henry T.D., Et al., The VIVA Trial: Vascular Endotheliall Growth Factor in Ischemia for Vascular Angiogenesis, Circulation, 107, pp. 1359-1365, (2003)

[4]

Simons M., Et al., Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial, Circulation, 105, pp. 788-793, (2002)

[5]

Lunde K., Et al., Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction, N Engl J Med, 355, pp. 1199-1209, (2006)

[6]

Assmus B., Et al., Transcoronary transplantation of progenitor cells after myocardial infarction, N Engl J Med, 355, pp. 1222-1232, (2006)

[7]

Losordo D.W., Et al., Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia, Circulation, 105, pp. 2012-2018, (2002)

[8]

Kastrup J., Et al., Euroinject One Group Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: The Euroinject One trial, J Am Coll Cardiol, 45, pp. 982-988, (2005)

[9]

Fuchs S., Et al., A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease, Catheter Cardiovasc Interv, 68, pp. 372-378, (2006)

[10]

Perin E.C., Et al., Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy, Circulation, 110, SUPPL. 1, (2004)

← 1 2 3 →